Amneal Pharmaceuticals Inc

AMRX remains in a Stage 2 advance, but the recent blow-off top candle with a long upper wick at key resistance and volume spike signals a potential terminal phase. Price is extended above the 9/21/50 EMA cluster and rejecting, making short‐term timing unfavorable. The medium‐term bias stays bullish in the absence of a breakdown, but execution is deferred: look to engage on a pullback into rising EMA support for trend continuation.

• ↑Forecasted 20.5% FY earnings growth backed by multiple product approvals.
• ↑Q1 revenue $720M (+3% YoY), adjusted EBITDA $184M (+13%), EPS $0.45 (+56%).
• ↓High leverage and 13F outflows indicate institutional skepticism on stability.